<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04750824</url>
  </required_header>
  <id_info>
    <org_study_id>1200-0335</org_study_id>
    <nct_id>NCT04750824</nct_id>
  </id_info>
  <brief_title>Real-World Effectiveness of Afatinib (Gilotrif) Following Immunotherapy in the Treatment of Metastatic, Squamous Cell Carcinoma of the Lung: A Multi-Site Retrospective Chart Review Study in the U.S.</brief_title>
  <official_title>Assessment of Real-World Outcomes Associated With Afatinib (Gilotrif) Use in Patients With Solid Tumors Harboring NRG1 Gene Fusions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Characteristics of patients with Neuregulin-1 (NRG1) gene fusion-positive solid tumors&#xD;
      treated with afatinib, and characteristics of those treated with another systemic therapy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 15, 2020</start_date>
  <completion_date type="Actual">September 17, 2021</completion_date>
  <primary_completion_date type="Actual">September 17, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients with a complete response (CR) or partial response (PR)</measure>
    <time_frame>1 day</time_frame>
    <description>out of all patients (CR+PR/all patients) at initial response assessment and best response</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of clinical benefit (DOCB)</measure>
    <time_frame>1 day</time_frame>
    <description>time from initial response (for any patient with a complete, partial, or stable disease response initially) until the earliest of either disease progression or death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response</measure>
    <time_frame>1 day</time_frame>
    <description>time from initial response (for any patient with a complete or partial response initially) until the earliest of either disease progression or death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time from initiation of a line of therapy until discontinuation for any reason</measure>
    <time_frame>1 day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time from initiation of a line of therapy until discontinuation due to disease progression</measure>
    <time_frame>1 day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time from initiation of a line of therapy until disease progression or death</measure>
    <time_frame>1 day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time from initiation of any therapy in the metastatic setting until death</measure>
    <time_frame>1 day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients experiencing an adverse event</measure>
    <time_frame>1 day</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">110</enrollment>
  <condition>Non-squamous, Non-Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Afatinib cohort</arm_group_label>
    <description>Afatinib cohort</description>
  </arm_group>
  <arm_group>
    <arm_group_label>other systemic therapy cohort</arm_group_label>
    <description>other systemic therapy cohort</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Afatinib</intervention_name>
    <description>Afatinib</description>
    <arm_group_label>Afatinib cohort</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>other systemic therapy</intervention_name>
    <description>other systemic therapy</description>
    <arm_group_label>other systemic therapy cohort</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Providers will select patients meeting the study eligibility criteria as described below.&#xD;
        Providers will be asked to select eligible patients chronologically, starting with the&#xD;
        first patient who first initiated any line of afatinib or chemotherapy, on or after&#xD;
        01/01/2017 through 03/31/2020.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adults, 18 years of age or older, at the time of diagnosis with any solid tumor.&#xD;
&#xD;
          -  Confirmed NRG1 gene fusion in any solid tumor.&#xD;
&#xD;
          -  Initiated afatinib or other systemic therapy (in any line of therapy) for treatment of&#xD;
             a solid tumor with NRG1 gene fusion on or after 01/01/2017 through 03/31/2020.&#xD;
&#xD;
          -  Followed up for â‰¥3 months after initiation of afatinib or other systemic therapy&#xD;
             (unless deceased prior to 3 months of follow-up).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        - Treatment with any Tyrosine kinase inhibitor (TKI)/ErbB-directed therapy other than&#xD;
        afatinib&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Cardinal Health</name>
      <address>
        <city>Dublin</city>
        <state>Ohio</state>
        <zip>43017</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mystudywindow.com</url>
    <description>Related Info</description>
  </link>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>February 8, 2021</study_first_submitted>
  <study_first_submitted_qc>February 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 11, 2021</study_first_posted>
  <last_update_submitted>November 3, 2021</last_update_submitted>
  <last_update_submitted_qc>November 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Afatinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Clinical studies sponsored by Boehringer Ingelheim, phases I to IV, interventional and non-interventional, are in scope for sharing of the raw clinical study data and clinical study documents, except for the following exclusions:&#xD;
studies in products where Boehringer Ingelheim is not the license holder;&#xD;
studies regarding pharmaceutical formulations and associated analytical methods, and studies pertinent to pharmacokinetics using human biomaterials;&#xD;
studies conducted in a single center or targeting rare diseases (because of limitations with anonymization).&#xD;
For more details refer to: https://www.mystudywindow.com/msw/datasharing</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

